Renaissance Technologies LLC Has $18.26 Million Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL)

Renaissance Technologies LLC boosted its holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) by 39.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 685,000 shares of the company’s stock after buying an additional 195,438 shares during the quarter. Renaissance Technologies LLC owned approximately 2.45% of Castle Biosciences worth $18,255,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. R Squared Ltd acquired a new stake in shares of Castle Biosciences in the 4th quarter valued at approximately $42,000. KLP Kapitalforvaltning AS acquired a new stake in Castle Biosciences in the fourth quarter valued at approximately $128,000. China Universal Asset Management Co. Ltd. boosted its position in Castle Biosciences by 11.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,939 shares of the company’s stock valued at $158,000 after buying an additional 604 shares in the last quarter. Oak Harvest Investment Services bought a new stake in shares of Castle Biosciences during the fourth quarter worth $206,000. Finally, Janus Henderson Group PLC acquired a new position in shares of Castle Biosciences during the third quarter worth $261,000. Institutional investors own 92.60% of the company’s stock.

Castle Biosciences Stock Up 2.1 %

Shares of NASDAQ:CSTL opened at $19.70 on Monday. The business has a fifty day simple moving average of $22.34 and a 200 day simple moving average of $27.09. Castle Biosciences, Inc. has a 12-month low of $16.97 and a 12-month high of $35.84. The firm has a market cap of $568.13 million, a P/E ratio of 98.50 and a beta of 1.11. The company has a quick ratio of 7.64, a current ratio of 7.78 and a debt-to-equity ratio of 0.02.

Insider Transactions at Castle Biosciences

In other news, insider Derek J. Maetzold sold 2,130 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $19.52, for a total transaction of $41,577.60. Following the completion of the sale, the insider now directly owns 78,335 shares in the company, valued at $1,529,099.20. This represents a 2.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Daniel Bradbury sold 7,867 shares of Castle Biosciences stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $28.17, for a total transaction of $221,613.39. The disclosure for this sale can be found here. Insiders sold 34,085 shares of company stock worth $748,045 over the last ninety days. 7.20% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research firms recently weighed in on CSTL. Stephens reissued an “overweight” rating and set a $41.00 price objective on shares of Castle Biosciences in a report on Thursday, January 2nd. Guggenheim set a $30.00 target price on Castle Biosciences and gave the company a “buy” rating in a research report on Friday, March 28th. Finally, Robert W. Baird boosted their price target on Castle Biosciences from $36.00 to $37.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, Castle Biosciences currently has a consensus rating of “Buy” and an average target price of $38.75.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.